Cubist Pharmaceuticals, Inc. (CBST) Tops Q2 EPS by 18c, Revenues Beat Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall St climbs as oil slips; SpaceX spectrum deal weighs on telecoms
- Oil falls as Trump comments on Iran talks ease supply concerns
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts CBST Hot Sheet
Price: $101.94 --0%
Financial Fact:
Basic net (loss) income per common share (in shares): 75.83M
Today's EPS Names:
HOVR, VFS, PGR, More
Financial Fact:
Basic net (loss) income per common share (in shares): 75.83M
Today's EPS Names:
HOVR, VFS, PGR, More
Join SI Premium – FREE
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) reported Q2 EPS of $0.59, $0.18 better than the analyst estimate of $0.41. Revenue for the quarter came in at $176.8 million versus the consensus estimate of $174.82 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Misses Q3 EPS by 20c, Beats on Revenue; Cuts FY EPS Guidance
- Neogen Corp. (NEOG) Tops Q1 EPS by 3c
- Delta Air Lines Q3 earnings preview: stronger print expected, fuel impact in focus
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
